The interleukin-2 market is experiencing rapid expansion, fueled by increasing cancer immunotherapy adoption, autoimmune disorder research, and essential roles in CAR-T and NK cell treatments. Major companies driving this growth include Novartis (Proleukin), Alkermes, NeoImmuneTech, Eli Lilly, and Nektar Therapeutics.
Advanced engineered IL-2 formulations and strategic combination approaches are accelerating breakthroughs in this thriving immunology space, offering substantial growth potential for industry stakeholders.
Explore comprehensive IL-2 market data and projections:
https://www.delveinsight.com/i....nfographics/interleu
Comment
Share
